Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant

Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a...

Full description

Saved in:
Bibliographic Details
Published in:ACG case reports journal 2024-04, Vol.11 (4), p.e01327
Main Authors: Khan, Sarosh Ahmed, Zahid, Rida, Amir, Muhammad
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3
cites cdi_FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3
container_end_page
container_issue 4
container_start_page e01327
container_title ACG case reports journal
container_volume 11
creator Khan, Sarosh Ahmed
Zahid, Rida
Amir, Muhammad
description Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation.
doi_str_mv 10.14309/crj.0000000000001327
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_14309_crj_0000000000001327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38586821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3</originalsourceid><addsrcrecordid>eNpdkNtKw0AQQBdRbKn9BGV_IHUv2c3mUYvaQECQ9jnMXiJb2iTsbgv-vdGqFOdlLswZhoPQLSULmnNS3puwXZCzoJwVF2jKOJMZZ4JfntUTNI9x-7WUy4KX9BpNuBJKKkanqNoMYMH45Duvs6qzB-MsXrkB0jiL-BG_OTDJH8e-73DtwPruHace1_7oAl4H6OKwgy7doKsWdtHNf_IMbZ6f1stVVr--VMuHOjPjLykDQ0ROjWW5ljkAF0YXhQatDaFMEqItJWXRcqEgbxk3BETLaCkV0UaCAj5D4nTXhD7G4NpmCH4P4aOhpPm204x2mv92Ru7uxA0HvXf2j_p1wT8BAodgSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant</title><source>PubMed (Medline)</source><source>Lippincott Williams &amp; Wilkins</source><creator>Khan, Sarosh Ahmed ; Zahid, Rida ; Amir, Muhammad</creator><creatorcontrib>Khan, Sarosh Ahmed ; Zahid, Rida ; Amir, Muhammad</creatorcontrib><description>Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation.</description><identifier>ISSN: 2326-3253</identifier><identifier>EISSN: 2326-3253</identifier><identifier>DOI: 10.14309/crj.0000000000001327</identifier><identifier>PMID: 38586821</identifier><language>eng</language><publisher>United States</publisher><ispartof>ACG case reports journal, 2024-04, Vol.11 (4), p.e01327</ispartof><rights>2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3</citedby><cites>FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38586821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Sarosh Ahmed</creatorcontrib><creatorcontrib>Zahid, Rida</creatorcontrib><creatorcontrib>Amir, Muhammad</creatorcontrib><title>Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant</title><title>ACG case reports journal</title><addtitle>ACG Case Rep J</addtitle><description>Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation.</description><issn>2326-3253</issn><issn>2326-3253</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkNtKw0AQQBdRbKn9BGV_IHUv2c3mUYvaQECQ9jnMXiJb2iTsbgv-vdGqFOdlLswZhoPQLSULmnNS3puwXZCzoJwVF2jKOJMZZ4JfntUTNI9x-7WUy4KX9BpNuBJKKkanqNoMYMH45Duvs6qzB-MsXrkB0jiL-BG_OTDJH8e-73DtwPruHace1_7oAl4H6OKwgy7doKsWdtHNf_IMbZ6f1stVVr--VMuHOjPjLykDQ0ROjWW5ljkAF0YXhQatDaFMEqItJWXRcqEgbxk3BETLaCkV0UaCAj5D4nTXhD7G4NpmCH4P4aOhpPm204x2mv92Ru7uxA0HvXf2j_p1wT8BAodgSw</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Khan, Sarosh Ahmed</creator><creator>Zahid, Rida</creator><creator>Amir, Muhammad</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202404</creationdate><title>Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant</title><author>Khan, Sarosh Ahmed ; Zahid, Rida ; Amir, Muhammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Sarosh Ahmed</creatorcontrib><creatorcontrib>Zahid, Rida</creatorcontrib><creatorcontrib>Amir, Muhammad</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>ACG case reports journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Sarosh Ahmed</au><au>Zahid, Rida</au><au>Amir, Muhammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant</atitle><jtitle>ACG case reports journal</jtitle><addtitle>ACG Case Rep J</addtitle><date>2024-04</date><risdate>2024</risdate><volume>11</volume><issue>4</issue><spage>e01327</spage><pages>e01327-</pages><issn>2326-3253</issn><eissn>2326-3253</eissn><abstract>Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation.</abstract><cop>United States</cop><pmid>38586821</pmid><doi>10.14309/crj.0000000000001327</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2326-3253
ispartof ACG case reports journal, 2024-04, Vol.11 (4), p.e01327
issn 2326-3253
2326-3253
language eng
recordid cdi_crossref_primary_10_14309_crj_0000000000001327
source PubMed (Medline); Lippincott Williams & Wilkins
title Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A21%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Upadacitinib-Induced%20Hepatitis%20B%20Reactivation%20Leading%20to%20Liver%20Transplant&rft.jtitle=ACG%20case%20reports%20journal&rft.au=Khan,%20Sarosh%20Ahmed&rft.date=2024-04&rft.volume=11&rft.issue=4&rft.spage=e01327&rft.pages=e01327-&rft.issn=2326-3253&rft.eissn=2326-3253&rft_id=info:doi/10.14309/crj.0000000000001327&rft_dat=%3Cpubmed_cross%3E38586821%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c253t-ac0541cd24b64aa35cb77babbc012600bd1097f358a4f23c0a5f219680bc6a8a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/38586821&rfr_iscdi=true